Ter Arkh. 2012;84(4):57-63.
Pulmonary hypertension is a rather frequent pathophysiological and hemodynamic condition detectable in many clinical situations including pulmonary and cardiac diseases. Pulmonary arterial hypertension (pAH) is a specific clinical group of severe and rare diseases with similar morphological, hemodynamic and therapeutic characteristics. PAH diagnosis is confirmed by catheterization of the right heart. Special pharmacotherapy has been developed of late for PAH-oriented treatment. PAH is a progressive disease and therefore demands continuous monitoring and escalation of pharmacotherapy if therapeutic targets fail to be achieved with monotherapy. Combined treatment of PAH seems to be optimal now.
肺动脉高压是一种在包括肺部和心脏疾病在内的许多临床情况下都可检测到的相当常见的病理生理和血流动力学状况。肺动脉高压（pAH）是一组具有相似形态、血流动力学和治疗特征的严重且罕见疾病的特定临床类型。pAH的诊断通过右心导管检查得以证实。近来已研发出针对pAH的特殊药物疗法用于治疗。pAH是一种进行性疾病，因此如果单一疗法未能实现治疗目标，就需要持续监测并加强药物治疗。目前，pAH的联合治疗似乎是最佳选择。
